Eptinezumab safe and effective for treatment of migraine

Key clinical point: Eptinezumab, particularly at a dosage of 300 mg, has significant efficacy and an acceptable safety profile for treatment of migraine.

Major finding: Eptinezumab significantly reduced the mean monthly migraine days (MMDs) compared with placebo at week 12 at a dosage of 30 mg (change in MMDs, −0.29; P = .0001), 100 mg (change in MMDs, −0.31; P less than .00001), and 300 mg (change in MMDs, −0.41; P less than .00001). Treatment-emergent adverse events were not significantly different between eptinezumab and placebo.

Study details: This was a meta-analysis of 4 randomized controlled trials including 2,739 patients with migraine.

Disclosures: This work was supported by the Suzhou Health Talents Training Project. The authors declared no competing interests.

Source: Yan Z et al. J Headache Pain. 2021 Mar 6. doi: 10.1186/s10194-021-01220-y.

Key clinical point: Eptinezumab, particularly at a dosage of 300 mg, has significant efficacy and an acceptable safety profile for treatment of migraine.

Major finding: Eptinezumab significantly reduced the mean monthly migraine days (MMDs) compared with placebo at week 12 at a dosage of 30 mg (change in MMDs, −0.29; P = .0001), 100 mg (change in MMDs, −0.31; P less than .00001), and 300 mg (change in MMDs, −0.41; P less than .00001). Treatment-emergent adverse events were not significantly different between eptinezumab and placebo.

Study details: This was a meta-analysis of 4 randomized controlled trials including 2,739 patients with migraine.

Disclosures: This work was supported by the Suzhou Health Talents Training Project. The authors declared no competing interests.

Source: Yan Z et al. J Headache Pain. 2021 Mar 6. doi: 10.1186/s10194-021-01220-y.

Key clinical point: Eptinezumab, particularly at a dosage of 300 mg, has significant efficacy and an acceptable safety profile for treatment of migraine.

Major finding: Eptinezumab significantly reduced the mean monthly migraine days (MMDs) compared with placebo at week 12 at a dosage of 30 mg (change in MMDs, −0.29; P = .0001), 100 mg (change in MMDs, −0.31; P less than .00001), and 300 mg (change in MMDs, −0.41; P less than .00001). Treatment-emergent adverse events were not significantly different between eptinezumab and placebo.

Study details: This was a meta-analysis of 4 randomized controlled trials including 2,739 patients with migraine.

Disclosures: This work was supported by the Suzhou Health Talents Training Project. The authors declared no competing interests.

Source: Yan Z et al. J Headache Pain. 2021 Mar 6. doi: 10.1186/s10194-021-01220-y.